This study will be conducted on women of reproductive age diagnosed with idiopathic overactive bladder who either do not want to use drug treatment or cannot tolerate it due to side effects. Our aim is to examine the effects of a treatment method called transcutaneous tibial nerve stimulation on overactive bladder symptoms, urine flow measurements (uroflowmetry), post-voiding residue, pelvic floor muscle activity, heart rate variability, and quality of life in these individuals.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incontinence Impact Questionnaire scale
Timeframe: From enrollment to the end of treatment at 6 weeks
Overactive bladder validation score 8
Timeframe: From enrollment to the end of treatment at 6 weeks
Voiding volume
Timeframe: From enrollment to the end of treatment at 6 weeks
Voiding time
Timeframe: From enrollment to the end of treatment at 6 weeks
Maximum flow rate
Timeframe: From enrollment to the end of treatment at 6 weeks
Time to reach maximum flow
Timeframe: From enrollment to the end of treatment at 6 weeks
Average flow rate
Timeframe: From enrollment to the end of treatment at 6 weeks
Post-voiding residual urine
Timeframe: From enrollment to the end of treatment at 6 weeks
SDNN (msn)
Timeframe: From enrollment to the end of treatment at 6 weeks
RMSSD (msn)
Timeframe: From enrollment to the end of treatment at 6 weeks
pNN50 (%)
Timeframe: From enrollment to the end of treatment at 6 weeks
TP (msn²)
Timeframe: From enrollment to the end of treatment at 6 weeks
LF (msn²), %LF, LFnorm
Timeframe: From enrollment to the end of treatment at 6 weeks
HF (msn²), %HF, HFnorm
Timeframe: From enrollment to the end of treatment at 6 weeks
LF/HF (msn²)
Timeframe: From enrollment to the end of treatment at 6 weeks
Pelvic Floor Muscle-Contraction average (ÎĽV)
Timeframe: From enrollment to the end of treatment at 6 weeks
Pelvic floor muscle contraction MVC (%)
Timeframe: From enrollment to the end of treatment at 6 weeks
Pelvic floor muscle relaxation mean (ÎĽV)
Timeframe: From enrollment to the end of treatment at 6 weeks
Pelvic floor muscle relaxation MVC (%)
Timeframe: From enrollment to the end of treatment at 6 weeks
Pelvic floor muscle contraction onset (s)
Timeframe: From enrollment to the end of treatment at 6 weeks